5 Key Takeaways

• 1

  The FDA approval of anti-myopia spectacles marks a significant advancement in myopia management accessibility in the U.S.

• 2

  Anti-myopia spectacles offer a non-invasive option for early myopia management, especially for younger children and pre-myopes.

• 3

  Ortho-k provides unique advantages, such as customized myopic defocus and strong evidence for slowing axial elongation.

• 4

  Patient education and consistent follow-up are crucial for the efficacy of both spectacles and ortho-k interventions.

• 5

  The introduction of anti-myopia spectacles expands the myopia management conversation, encouraging more families to engage in eye care.